Imfinzi, in a Phase III trial called 'PEARL', failed in patients whose tumour cells express high levels of PD-L1, or in a subgroup of patients at low risk of early mortality, AstraZeneca said in a statement.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/yDbFnA2
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» AstraZeneca drug Imfinzi fails as monotherapy for type of lung cancer
https://ift.tt/tzj948y
No comments:
Post a Comment